Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
about
The Cryptococcus neoformans capsule: a sword and a shield.Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in miceCharacterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyAntibody interactions with the capsule of Cryptococcus neoformansFc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificityBinding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophagesPathogenesis of pulmonary Cryptococcus neoformans infection in the ratEvaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Production and characterization of murine monoclonal antibodies to Histoplasma capsulatum yeast cell antigensCharacterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis.A xylosylphosphotransferase of Cryptococcus neoformans acts in protein O-glycan synthesis.Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigenMultiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformansProduction of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformansThe mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluidSerotyping of Cryptococcus neoformans by dot enzyme assay.Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharidesThe glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigenA 34- to 38-kilodalton Cryptococcus neoformans glycoprotein produced as an exoantigen bearing a glycosylated species-specific epitope.Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens.Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.Production of species-specific murine monoclonal antibodies against Cryptococcus neoformans which recognize a noncapsular exoantigen.Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage.The capsule of the fungal pathogen Cryptococcus neoformans.Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule
P2860
Q24619875-912504B4-5EDB-4D8B-8711-43C94C75F74CQ33602561-1615E116-A755-4E6C-9441-736ABE3155ACQ33751509-A62E73B4-824A-49B3-8012-C5ADEB273E52Q33752366-9A5066CE-5BC0-4E68-AA32-851338A78C7BQ33752377-4D2D1D37-4B67-4389-9D0E-09D12DCB8EB4Q34001243-B0BB25FE-DAEF-4D35-B86C-6838FF481AA3Q34001769-6DBFECC5-060B-4008-9188-BF94DF432E3DQ34004832-556E4866-1622-40B9-908A-B29E2F7A4E26Q34123230-457C84EA-3B59-45A0-B30D-CE2494A8F145Q34301177-B0A68EBF-4823-4A11-AF99-B00ED4FB5DA5Q34543565-6FCEAD6F-A5FB-4F90-8519-5A6E4B572EEBQ34594241-570A60DB-5E07-4364-937D-E982F18CE74DQ34779166-69E75A7F-B7BC-4573-893E-30DE72B58489Q35092723-6F238D9F-4254-4FEE-8294-A66D675AC9AFQ35097097-F684F309-A48D-46A2-9D15-587AD97BD32CQ35128286-105C132A-213E-4A9D-8603-B76EF08D30E1Q35138768-8C770696-A1FB-4B87-BF20-1E67C6E5A968Q35197055-14867F28-EC68-4BC1-8072-20A6C8F91A87Q35225603-DF40054F-3F7A-4E34-840E-816B29E487F5Q35409786-60F5F24F-3583-4D7C-B921-9AAA18F31B21Q35567548-AA4A8D1D-6679-4953-9720-D1162D335F3EQ35923662-49B0243C-6570-4050-8EFD-8A40600439D5Q36230201-B49506BF-9617-414C-B2F8-E4401CB3E6E5Q36361541-C125BDBC-C184-4078-8606-77AB5F465EDFQ36456615-8C3F50CA-84A6-4883-82E0-09EAE016587DQ36504837-190BAC64-C2B3-4CD3-B5A5-3DD5CD9B3D4FQ36527966-C09F3DAF-A31B-4B93-ADC5-F4F499DD4AB0Q36662728-817D61BE-19D9-4D4B-B6CF-F8D6AD770B5BQ36951576-9150C2F8-1206-44CB-A6FA-89036B2194F6Q36954091-7043F4A5-D15C-4C96-BD8B-82240653B626Q36984485-298F455C-1184-4B4B-938B-5FF6EA0A473DQ36988205-A0FB48C2-9B2A-452F-9773-20C8C129EF7FQ36993744-7A8C8668-93DD-46EB-955E-73F03F5E5F7BQ37007244-EC1F3B3C-1D47-4BCB-85F4-C2FBEB96E751Q37025361-2043689F-692D-4A90-9109-A0DD820A8475Q37051210-C373EA71-1671-48FA-ABF2-563FE1DB1D9DQ37234492-8182F061-2311-4746-B130-DC0536A94189Q37332530-E3EFA801-EE61-438E-A9FC-A20F81C241DFQ37337879-021B9E9A-2163-483E-A10F-31F115840CFBQ37459771-0565B080-C361-45F9-9C28-2BBA9BB52DBC
P2860
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1987
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Production and characterizatio ...... rmans capsular polysaccharide.
@en
Production and characterizatio ...... rmans capsular polysaccharide.
@nl
type
label
Production and characterizatio ...... rmans capsular polysaccharide.
@en
Production and characterizatio ...... rmans capsular polysaccharide.
@nl
prefLabel
Production and characterizatio ...... rmans capsular polysaccharide.
@en
Production and characterizatio ...... rmans capsular polysaccharide.
@nl
P2860
P1476
Production and characterizatio ...... ormans capsular polysaccharide
@en
P2093
P2860
P304
P407
P577
1987-08-01T00:00:00Z